Oral cytotoxic agent has a 43% response rate in patients with gliomas previously untreated with chemotherapy, a Phase II study presented at ASCO May 18 finds. A total of 44 patients were treated with the drug, which was "well tolerated with little subjective toxicity and predictable myelosuppression," the study abstract states. The trial was led by investigators at Charing Cross Hospital in London. Schering-Plough plans to conduct further research on the compound.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth